These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 21575799

  • 1. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR.
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [Abstract] [Full Text] [Related]

  • 2. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM, Lewis DF.
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [Abstract] [Full Text] [Related]

  • 3. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO, Stamilio DM, Macones GA, Polsky D.
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [Abstract] [Full Text] [Related]

  • 4. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
    Gonzalez-Quintero VH, Cordova YC, Istwan NB, Tudela F, Rhea DJ, Romary LM, Marimon A, Desch CN, Stanziano GJ.
    Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
    [Abstract] [Full Text] [Related]

  • 5. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC, Schoen CN, Frey H, Gimovsky AC, Springel E, Backley S, Berghella V.
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [Abstract] [Full Text] [Related]

  • 6. Progesterone for preterm birth prevention: an evolving intervention.
    Tita AT, Rouse DJ.
    Am J Obstet Gynecol; 2009 Mar; 200(3):219-24. PubMed ID: 19254577
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F, Vaccaro V.
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [Abstract] [Full Text] [Related]

  • 8. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K.
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [Abstract] [Full Text] [Related]

  • 9. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
    Coleman S, Wallace L, Alexander J, Istwan N.
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
    [Abstract] [Full Text] [Related]

  • 10. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ.
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [Abstract] [Full Text] [Related]

  • 11. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S.
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [Abstract] [Full Text] [Related]

  • 12. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 13. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
    Manuck TA.
    Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
    [Abstract] [Full Text] [Related]

  • 14. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
    Awwad J, Usta IM, Ghazeeri G, Yacoub N, Succar J, Hayek S, Saasouh W, Nassar AH.
    BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
    [Abstract] [Full Text] [Related]

  • 15. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM, Istwan NB, Palmer B, Stanziano GJ.
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [Abstract] [Full Text] [Related]

  • 16. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL, Walker HC, Hade EM, Iams JD.
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [Abstract] [Full Text] [Related]

  • 17. The use of progestational agents for preterm birth: lessons from a mouse model.
    Elovitz MA, Mrinalini C.
    Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
    [Abstract] [Full Text] [Related]

  • 18. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
    Caritis SN, Feghali MN, Grobman WA, Rouse DJ, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network.
    Semin Perinatol; 2016 Aug; 40(5):273-80. PubMed ID: 27105940
    [Abstract] [Full Text] [Related]

  • 19. Treatment options and recommendations to reduce preterm births in women with short cervix.
    Slager J, Lynne S.
    J Midwifery Womens Health; 2012 Jul; 57 Suppl 1():S12-8. PubMed ID: 22776244
    [Abstract] [Full Text] [Related]

  • 20. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Merlob P, Stahl B, Klinger G.
    Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.